Refine
Has Fulltext
- yes (7)
Is part of the Bibliography
- yes (7)
Document Type
- Journal article (7)
Language
- English (7) (remove)
Keywords
- B cell malignancies (1)
- B‐cell lymphoma (1)
- CD274 (1)
- Cancer genetics (1)
- EZH1 (1)
- EZH2 (1)
- H3K27me3 (1)
- Hodgkin lymphoma (1)
- Medical research (1)
- PTCL (1)
- Rituximab plus (1)
- T-cell non-Hodgkin's lymphomas (1)
- Translational research (1)
- USP9X (1)
- XIAP (1)
- c-myc (1)
- classical Hodgkin lymphoma (1)
- cyclophsophamide (1)
- distinct (1)
- epigenetics (1)
- fluorescence in situ hybridisation (1)
- follicular lymphoma (1)
- gene expression (1)
- gene regulation (1)
- genomic aberrations (1)
- grade 3B (1)
- growth patterns (1)
- immune checkpoint blockade (1)
- immunohistochemistry (1)
- machine learning (1)
- major histocompatibility complex (1)
- mitosis (1)
- molecular subtypes (1)
- next generation sequencing (1)
- poor prognosis (1)
- prognostic factor (1)
- relapse (1)
- tumor heterogeneity (1)
- ubiquitin (1)
Institute
High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced-stage or r/r cHL. All but two cases (97%) showed PD-L1 expression by the tumour cells in variable amounts. While MHC-I was rarely expressed in >50% of HRSC, MHC-II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD-L1 and MHC-I/II expression on early response to the highly effective anti-PD-1-based NIVAHL first-line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti-PD-1 first-line cHL treatment.